Description
Ultravist 300 (iopromide) Solution for Injection
Ultravist 300 is a sterile, nonpyrogenic solution for injection containing iopromide as the active ingredient. It is a radiographic contrast agent used for diagnostic imaging procedures. Each milliliter of Ultravist 300 contains 300 mg. of iopromide.
Composition
The main active ingredient in Ultravist 300 is iopromide. In addition to iopromide, the solution also contains other excipients to maintain stability and ensure compatibility with the body’s tissues.
Indications
Ultravist 300 is indicated for use in radiographic procedures where contrast enhancement is needed to improve visualization of blood vessels, organs, and tissues. It is commonly used in imaging studies such as angiography, computed tomography (CT), and intravenous urography.
Mechanism of Action
After injection, Ultravist 300 circulates in the bloodstream and is distributed to the areas being imaged. Iopromide is a radiocontrast agent that absorbs X-rays differently than surrounding tissues, providing improved contrast in the resulting images.
Dosage and Administration
Ultravist 300 is available in vials containing 100 ml. of the solution. The dosage and administration of Ultravist 300 should be individualized based on the specific imaging procedure being performed, the patient’s weight and medical condition, and other factors.
The solution is typically administered intravenously, and the rate of injection may vary depending on the imaging modality and the specific protocol being followed. It is essential to follow the dosing instructions provided by the healthcare provider or radiologist.
Contraindications
Ultravist 300 is contraindicated in patients with a known hypersensitivity to iopromide or any of the excipients in the formulation. Additionally, caution should be exercised in patients with a history of allergic reactions to other contrast agents or iodine-containing substances.
Warnings and Precautions
Prior to administration of Ultravist 300, healthcare providers should assess the patient’s medical history, including any allergies, kidney function, and risk factors for adverse reactions. Adequate hydration should be maintained before and after the procedure to help prevent contrast-induced nephropathy.
Special consideration should be given to patients with renal impairment, as iopromide is excreted primarily by the kidneys. Dosage adjustments may be necessary in these patients to minimize the risk of contrast-induced nephropathy.
Adverse Reactions
Common adverse reactions associated with Ultravist 300 include nausea, vomiting, headache, and injection site reactions. Serious adverse reactions, such as anaphylaxis, can occur in rare cases. Healthcare providers should be prepared to manage any allergic reactions or other adverse events that may arise.
Storage
Ultravist 300 should be stored at controlled room temperature, away from light and moisture. Do not freeze the solution, and discard any unused portion according to local regulations for the disposal of pharmaceutical waste.
Conclusion
Ultravist 300 is a radiographic contrast agent that provides enhanced visualization of blood vessels and tissues during diagnostic imaging procedures. It is an essential tool for radiologists and healthcare providers to obtain accurate and detailed images for diagnosis and treatment planning.
By following the recommended dosage and administration guidelines, monitoring for adverse reactions, and taking appropriate precautions in high-risk patients, Ultravist 300 can be used safely and effectively to improve the quality of diagnostic imaging studies.
